Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Unresectable Melanoma
NCT02120222Phase 1Completed
- Sponsor
- Kari Kendra
- Start
- Aug 2014
- Primary completion
- Apr 2018
- Countries
- 1
01
Overview
Phase 1, open-label trial of selinexor in melanoma, sponsored by Kari Kendra. Started Aug 2014; status: completed.
02
Drugs
selinexor
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02120222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120222.